TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11434846

Group type: EXPERIMENTAL
Intervention: Otikon Otic Solution (naturopathic herbal extract)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Anaesthetic ear drops (containing ametocaine and phenazone)
Number of subjects: 103
Study: 9517682

Group type: EXPERIMENTAL
Intervention: Buffered bupivacaine warmed to 37 degrees C
Number of subjects: 40

Group type: COMPARATOR
Intervention: Room temperature buffered bupivacaine (20 degrees)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unbuffered bupivacaine at room temperature
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unbuffered bupivacaine warmed to 37 degrees C
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Warmed bupivacaine to 37 degrees C
Number of subjects: 40
Study: 8281886

Group type: EXPERIMENTAL
Intervention: Low-fat diet and physical training (1 h twice weekly and daily bicycle ergometry for 30 min)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (physical training and low-fat diet based on own initiative)
Number of subjects: 36
Study: 2815173

Group type: EXPERIMENTAL
Intervention: Systemic metronidazole therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical local therapy
Number of subjects: 0
Study: 31154635

Group type: EXPERIMENTAL
Intervention: Participants who planned their messages
Number of subjects: 100

Group type: COMPARATOR
Intervention: Participants who did not plan their messages
Number of subjects: 100

Group type: COMPARATOR
Intervention: Participants (both planning and distraction conditions)
Number of subjects: 100
Study: 31199291

Group type: EXPERIMENTAL
Intervention: Treatment as Usual plus Videoconferencing (TAU-VC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 38
Study: 28495863

Group type: EXPERIMENTAL
Intervention: Soluble urokinase plasminogen activator receptor >11,633 pg/ml (third tertile)
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: Addition of soluble urokinase plasminogen activator receptor to a risk factor model
Number of subjects: 1175
Study: 25400106

Group type: COMPARATOR
Intervention: 0% L-arabinose in meal A (sucrose and starch from wheat flour)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5% L-arabinose in meal A (sucrose and starch from wheat flour)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 10% L-arabinose in meal A (sucrose and starch from wheat flour)
Number of subjects: 23

Group type: COMPARATOR
Intervention: 0% L-arabinose in meal B (starch from wheat flour)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 20% L-arabinose in meal B (starch from wheat flour)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Liquid meal with maltose and 0% L-arabinose
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Liquid meal with maltose and 20% L-arabinose
Number of subjects: 23
Study: 23497463

Group type: EXPERIMENTAL
Intervention: Training in depression screening and routine use of depression screening for at least 6 months (Intervention group).
Number of subjects: 3737

Group type: COMPARATOR
Intervention: Usual management of depression (Control group).
Number of subjects: 3737
Study: 21199857

Group type: EXPERIMENTAL
Intervention: 1-dose varicella vaccination
Number of subjects: 24488
Study: 18448495

Group type: EXPERIMENTAL
Intervention: bosentan
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 16458964

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fixed-combination latanoprost-timolol
Number of subjects: 28
Study: 14769716

Group type: EXPERIMENTAL
Intervention: Potassium-rich foods (diet)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Potassium chloride pills (medication)
Number of subjects: 48
Study: 11740309

Group type: EXPERIMENTAL
Intervention: SYN (evaporative polyester fabric)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: COT (traditional cotton fabric)
Number of subjects: 8

Group type: COMPARATOR
Intervention: S‐N (seminude)
Number of subjects: 8
Study: 8988937

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 12866

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12866
Study: 8406350

Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte-macrophage colony-stimulating factor (3, 1 or 0.5 micrograms/kg body wt)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte-macrophage colony-stimulating factor (3 micrograms/kg body wt)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte-macrophage colony-stimulating factor (0.5 to 1 microgram/kg body wt)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5 MU interferon-alpha 2b (in combination with GM-CSF)
Number of subjects: 9
Study: 2446054

Group type: EXPERIMENTAL
Intervention: Ketanserin (20‐80 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Alpha-methyldopa (500‐2000 mg daily)
Number of subjects: 20
Study: 31839432

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy in normal BMI and clinical stage IVA disease
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 253
Study: 31429794

Group type: EXPERIMENTAL
Intervention: Intravenous golimumab 2 mg/kg + methotrexate (MTX)
Number of subjects: 592

Group type: COMPARATOR
Intervention: Placebo + methotrexate (MTX)
Number of subjects: 592
Study: 28800444

Group type: EXPERIMENTAL
Intervention: New Forest Parenting Programme (NFPP)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Helping the Noncompliant Child (HNC)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 164
Study: 25224125

Group type: EXPERIMENTAL
Intervention: neuro-music therapy (counseling plus eight 50-minute sessions of individualized music therapy)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Counseling (50-minute individualized personal instruction)
Number of subjects: 290
Study: 23475018

Group type: EXPERIMENTAL
Intervention: Walking program (4 weeks)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Non-exercising group (control)
Number of subjects: 606
Study: 21595978

Group type: EXPERIMENTAL
Intervention: Tailored, iterative, printed dietary feedback (TF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small group nutrition education sessions (GE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-listed control (C)
Number of subjects: 0
Study: 19191657

Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Boosted atazanavir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Boosted protease inhibitor therapy (control)
Number of subjects: 0
Study: 16846509

Group type: EXPERIMENTAL
Intervention: 6 month clinical weight loss program
Number of subjects: 144

Group type: COMPARATOR
Intervention: Extended care treatment groups
Number of subjects: 144
Study: 14581010

Group type: EXPERIMENTAL
Intervention: ECG-gated MCTA (n=25, group 1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-ECG-gated MCTA (n=23, group 2)
Number of subjects: 48
Study: 10711591

Group type: EXPERIMENTAL
Intervention: Coping skills intervention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Disease-education control
Number of subjects: 67
Study: 9229195

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg, twice daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Acipimox and Placebo
Number of subjects: 16
Study: 8250301

Group type: EXPERIMENTAL
Intervention: Alfentanil 30 micrograms/kg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Alfentanil 60 micrograms/kg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Alfentanil (both doses)
Number of subjects: 23
Study: 4041341

Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg twice daily)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30483246

Group type: EXPERIMENTAL
Intervention: Novel therapeutic approaches targeting myofibroblasts
Number of subjects: 0
Study: 27389975

Group type: EXPERIMENTAL
Intervention: ABT-494 (3, 6, 12, or 18 mg twice daily)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: ABT-494 (12 and 18 mg)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: ABT-494 (6-18 mg)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 24535356

Group type: EXPERIMENTAL
Intervention: Patient-involved digital design and esthetic outcome prediction using CAD and CAM techniques.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group used regular design method for restoration.
Number of subjects: 32
Study: 22673191

Group type: EXPERIMENTAL
Intervention: Genetic information
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Gene-environment interaction information
Number of subjects: 396

Group type: COMPARATOR
Intervention: Non-genetic (environment) information
Number of subjects: 396
Study: 20582466

Group type: EXPERIMENTAL
Intervention: Pq1wC (paclitaxel 60 mg/m(2) days 1, 8, 15, carboplatin AUC 6 day 1 for every 3 weeks)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Pq3wC (paclitaxel 175 mg/m(2) day 1, carboplatin AUC 6 d1, every 3 weeks)
Number of subjects: 213
Study: 18618000

Group type: EXPERIMENTAL
Intervention: Common susceptibility and protective haplotypes at the CHRNA5-A3-B4 locus
Number of subjects: 2827

Group type: EXPERIMENTAL
Intervention: AA versus BC diplotype frequency
Number of subjects: 2827

Group type: EXPERIMENTAL
Intervention: AA versus CC diplotype frequency
Number of subjects: 2827

Group type: EXPERIMENTAL
Intervention: Genetic effect
Number of subjects: 2827
Study: 15894954

Group type: EXPERIMENTAL
Intervention: Early use of a novel undergarment
Number of subjects: 430

Group type: COMPARATOR
Intervention: Usual care of the institution
Number of subjects: 430
Study: 12061945

Group type: EXPERIMENTAL
Intervention: riluzole 100 mg/day (50 mg b.i.d.)
Number of subjects: 516

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 516
Study: 11956263

Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin‐RT (CRT) - cisplatin 40 mg/m² weekly for up to 8 weeks with radical RT
Number of subjects: 350

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin‐RT (CRT)
Number of subjects: 350
Study: 9714025

Group type: EXPERIMENTAL
Intervention: Postdilution HDF (POD-HDF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predilution HDF (PRD-HDF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis (HD)
Number of subjects: 0
Study: 7978475

Group type: EXPERIMENTAL
Intervention: TTSF-75 patch (75 micrograms/h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TTSF-50 patch (50 micrograms/h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TTSF-50 and TTSF-75 patches
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TTSF patches
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TTSF-75 patch
Number of subjects: 120
Study: 3173046

Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31812719

Group type: EXPERIMENTAL
Intervention: 5 Gy × 5 fractions of precision radiation therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: 4 Gy × 5 fractions (control group)
Number of subjects: 40
Study: 31551314

Group type: EXPERIMENTAL
Intervention: BEAMing
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: ddPCR
Number of subjects: 363

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 363
Study: 27518833

Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate (MAL) and intense pulsed light (IPL)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo and intense pulsed light (IPL)
Number of subjects: 37
Study: 25497513

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering treatment (target SBP <140 mmHg within 1 hour)
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Guideline‐recommended blood pressure lowering treatment (target SBP <180 mmHg)
Number of subjects: 2839
Study: 23866184

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Successful microcirculatory reperfusion (MBG 2/3)
Number of subjects: 452
Study: 21790298

Group type: EXPERIMENTAL
Intervention: Medikinet retard (50% immediate release)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Medikinet retard (lower daily dose, similar IR components in the morning)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Concerta (22% immediate release)
Number of subjects: 113
Study: 18052991

Group type: EXPERIMENTAL
Intervention: Galvanic skin response (GSR) during painful stimulation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Premature infant pain profile (PIPP) during painful stimulation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Galvanic skin response (GSR) and PIPP
Number of subjects: 32
Study: 16627305

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of Methadone
Number of subjects: 0
Study: 14619197

Group type: EXPERIMENTAL
Intervention: Extended transthoracic resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transhiatal resection
Number of subjects: 0
Study: 10885046

Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg for males and 0.5 g/kg for females)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8816142

Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐α (IFN‐α)
Number of subjects: 240
Study: 1553858

Group type: EXPERIMENTAL
Intervention: Indomethacin (intervention to suppress renal prostaglandins)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study: 31874891

Group type: EXPERIMENTAL
Intervention: Incentivised-peer-networks
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Peer-navigator-distribution
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 12000
Study: 29898169

Group type: EXPERIMENTAL
Intervention: Flipchart (serial album) used in intervention group (IG)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 112
Study: 26484950

Group type: EXPERIMENTAL
Intervention: IRB members
Number of subjects: 694

Group type: COMPARATOR
Intervention: Transplant surgeons and OPO professionals
Number of subjects: 694
Study: 24842596

Group type: EXPERIMENTAL
Intervention: Year-framed message (associated with lower levels of snacking)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Day-framed message
Number of subjects: 95
Study: 22502839

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) 30min per day, 5 days per week for 12 weeks (n=37)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group without TEAS treatment (n=39)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 76
Study: 19486478

Group type: EXPERIMENTAL
Intervention: Seated knee extension
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Straight leg raise
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Standing on one leg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: ACL reconstruction
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hamstring activation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All exercises tested
Number of subjects: 19
Study: 17361105

Group type: EXPERIMENTAL
Intervention: HSP90 inhibitor 17-allylaminogeldanamycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RACK1
Number of subjects: 0
Study: 16475452

Group type: EXPERIMENTAL
Intervention: Plastic glass
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Straw
Number of subjects: 18

Group type: COMPARATOR
Intervention: Directly from bottle
Number of subjects: 18
Study: 11899948

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg after a high-fat meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tibolone 2.5 mg after fasting
Number of subjects: 24
Study: 10365903

Group type: EXPERIMENTAL
Intervention: Screening group with polypectomy
Number of subjects: 799

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 799
Study: 7572695

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 4159

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 4159
Study: 1675520

Group type: EXPERIMENTAL
Intervention: Flagellum ELISA
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Capture ELISA
Number of subjects: 200

Group type: COMPARATOR
Intervention: IgM Western blot
Number of subjects: 200

Group type: COMPARATOR
Intervention: IgG Western blot
Number of subjects: 200
Study: 7341547

Group type: EXPERIMENTAL
Intervention: d,1-Carnitine (3 g/daily)
Number of subjects: 20
Study: 30308560

Group type: EXPERIMENTAL
Intervention: AAV2-REP1 gene therapy (0.1-mL subretinal injection of 10 genome particles)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AAV2-REP1 gene therapy
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control eyes
Number of subjects: 6
Study: 30562305

Group type: EXPERIMENTAL
Intervention: 16-week resistance training (RT) intervention
Number of subjects: 23

Group type: COMPARATOR
Intervention: Usual care waitlist control group
Number of subjects: 23
Study: 28386035

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 7020

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 7020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7020
Study: 26450511

Group type: EXPERIMENTAL
Intervention: OFD plus PTGs
Number of subjects: 63

Group type: COMPARATOR
Intervention: OFD
Number of subjects: 63
Study: 25154896

Group type: EXPERIMENTAL
Intervention: 6.4% glucose (CHO) solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study: 22101206

Group type: EXPERIMENTAL
Intervention: Staff-supported intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-guided comparison group
Number of subjects: 0
Study: 19708632

Group type: EXPERIMENTAL
Intervention: Polyethylene liner cementation in asymptomatic patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Polyethylene liner cementation in symptomatic patients
Number of subjects: 34
Study: 17606839

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 5 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide 2.5 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Amiloride 40 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide
Number of subjects: 51
Study: 15249932

Group type: EXPERIMENTAL
Intervention: EKN1 gene polymorphisms
Number of subjects: 148
Study: 11242483

Group type: EXPERIMENTAL
Intervention: 74SeO3(2‐)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 76SeO4(2‐)
Number of subjects: 10
Study: 9738377

Group type: EXPERIMENTAL
Intervention: Reversed tip and snip technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Divide and conquer technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Reversed tip and snip technique (patients 1-30)
Number of subjects: 60
Study: 8052271

Group type: EXPERIMENTAL
Intervention: Plasma supernatant from platelet concentrates
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cells from platelet concentrates
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Plasma supernatant
Number of subjects: 12
Study: 2929404

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus prednisone
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patients with preserved right ventricular function
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patients with right ventricular diastolic dysfunction (right ventricular end-diastolic pressure >= 11 mm Hg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patients with left ventricular ejection fraction less than 20%
Number of subjects: 52
Study: 30854904

Group type: EXPERIMENTAL
Intervention: Trochanteric surface irregularities including frank spurs protruding ⩾2 mm
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (100 patients with hip osteoarthritis or intracapsular neck of femur fracture)
Number of subjects: 38
Study: 31142359

Group type: EXPERIMENTAL
Intervention: 5 Hz TEAS
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 100 Hz TEAS
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Mixed TEAS
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo TEAS
Number of subjects: 156
Study: 27776752

Group type: EXPERIMENTAL
Intervention: Hypothermia for neonatal hypoxic-ischemic encephalopathy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No hypothermia (control group)
Number of subjects: 0
Study: 26420002

Group type: EXPERIMENTAL
Intervention: Touch Massage (TM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rest (Control)
Number of subjects: 20
Study: 23524524

Group type: EXPERIMENTAL
Intervention: Peg‐INFα‐2a
Number of subjects: 78

Group type: COMPARATOR
Intervention: Peg‐INFα‐2b
Number of subjects: 78
Study: 21412168

Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m intravenous) weekly on day 2 + phenoxodiol (3 mg/kg) weekly on days 1 and 2
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m IV) weekly on day 2 + phenoxodiol (3 mg/kg) weekly on days 1 and 2
Number of subjects: 32
Study: 19638927

Group type: EXPERIMENTAL
Intervention: LigaSure vessel sealing system (VS group)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Conventional clamp crushing method (CC group)
Number of subjects: 165
Study: 17536130

Group type: EXPERIMENTAL
Intervention: BEEF (n = 14)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CHICKEN (n = 15)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CARB (n = 14)
Number of subjects: 54

Group type: COMPARATOR
Intervention: CON (n = 11)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All ER groups combined
Number of subjects: 54